SFTPB and neoplasm: Here, we found that 34%-43% of rNSCLC patients have lower surfactant protein B precursor (pro-SFTPB) expression in tumor compared to adjacent tissues, and this low expression of pro-SFTPB is associated with low major pathological response to neoadjuvant chemoimmunotherapy and recurrence in rNSCLC.